P.8.1 Muscle biopsy findings in Limb Girdle muscle Dystrophy 2I (LGMD2I)

2013 ◽  
Vol 23 (9-10) ◽  
pp. 779-780
Author(s):  
S. Lindal ◽  
K. Myreng ◽  
S. Løseth ◽  
C. Jonsrud ◽  
M. Alhamidi ◽  
...  
2017 ◽  
Vol 8 ◽  
Author(s):  
Roman V. Deev ◽  
Sergei N. Bardakov ◽  
Mikhail O. Mavlikeev ◽  
Ivan A. Yakovlev ◽  
Zoya R. Umakhanova ◽  
...  

2019 ◽  
Vol 9 (3) ◽  
pp. 40-55
Author(s):  
S. N. Bardakov ◽  
R. V. Deev ◽  
M. O. Mavlikeev ◽  
Z. R. Umakhanova ◽  
P. G. Akhmedova ◽  
...  

2014 ◽  
Vol 18 (3) ◽  
pp. 404-408 ◽  
Author(s):  
S. Saredi ◽  
S. Gibertini ◽  
A. Ardissone ◽  
I. Fusco ◽  
S. Zanotti ◽  
...  

2018 ◽  
pp. 57-59
Author(s):  
Naglaa M. Kamal ◽  
Hamed A. Alghamdi ◽  
Abdulrahman Halabi ◽  
Abdullah O. Alharbi ◽  
Muhammad Rafique ◽  
...  

2020 ◽  
Vol 20 (5) ◽  
pp. 385-395
Author(s):  
Jon Walters ◽  
Atik Baborie

Skeletal muscle biopsy remains an important investigative tool in the diagnosis of a variety of muscle disorders. Traditionally, someone with a limb-girdle muscle weakness, myopathic changes on electrophysiology and raised serum creatine kinase (CK) would have a muscle biopsy. However, we are living through a genetics revolution, and so do all such patients still need a biopsy? When should we undertake a muscle biopsy in patients with a distal, scapuloperoneal or other patterns of muscle weakness? When should patients with myositis, rhabdomyolysis, myalgia, hyperCKaemia or a drug-related myopathy have a muscle biopsy? What does normal muscle histology look like and what changes occur in neurogenic and myopathic disorders? As with Kipling’s six honest serving men, we hope that by addressing these issues we can all become more confident about when to request a muscle biopsy and develop clearer insights into muscle pathology.


2005 ◽  
Vol 63 (2a) ◽  
pp. 235-245 ◽  
Author(s):  
Enio Alberto Comerlato ◽  
Rosana Hermínia Scola ◽  
Lineu César Werneck

The limb-girdle muscle dystrophy (LGMD) represents a heterogeneous group of muscular diseases with dominant and recessive inheritance, individualized by gene mutation. A group of 56 patients, 32 males and 24 females, with suggestive LGMD diagnosis were submitted to clinical evaluation, serum muscle enzymes, electromyography, muscle biopsy, and the immunoidentification (ID) of sarcoglycans (SG) alpha, beta, gamma and delta, dysferlin and western blot for calpain-3. All the patients had normal ID for dystrophin (rod domain, carboxyl and amine terminal). The alpha-SG was normal in 42 patients, beta-SG in 28, beta-SG in 45, delta-SG in 32, dysferlin in 37 and calpain-3 in 9. There was a reduction in the alpha-SG in 7 patients, beta-SG in 4, gamma-SG in 2, and delta-SG in 8. There was deficiency of alpha-SG in 7 patients, beta-SG in 6, gamma-SG in 9, delta-SG in 5, dysferlin in 8, and calpain-3 in 5. The patients were grouped according the ID as sarcoglycans deficiency 18 cases, dysferlin deficiency 8 cases and calpain-3 deficiency 5 cases. Only the sarcoglycans deficiency group showed calf hypertrophy. The dysferlin deficiency group was more frequent in females and the onset was later than sarcoglycan and calpain-3 deficiency groups. The calpain-3 deficiency group occurred only in males and showed an earlier onset and weaker muscular strength.


The first case of tick-borne encephalitis (TBE) in Lithuania, diagnosed by clinical and epidemiologic criteria only, was reported in 1953. A forest worker became ill with the disease in April after a tick bite, had a typical clinical presentation with shoulder girdle muscle paralysis and bulbar syndrome, and died after 12 days from the start of clinical symptoms. Autopsy data were compatible with viral encephalitis.1 Serological diagnosis of TBE in Lithuania was started in 1970.2


Sign in / Sign up

Export Citation Format

Share Document